Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics (TRDA) announced an independent monitoring committee’s recommendation to initiate the highest-dose cohort in its Phase 1/2 ELEVATE-44-201 study.
The committee reviewed available safety and pharmacokinetic data, measuring drug exposure, from eight Cohort 2 participants. It recommended 18 mg/kg for Cohort 3, following 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1. The study evaluates ENTR-601-44 for Duchenne muscular dystrophy in participants whose mutations are amenable to exon 44 skipping. Cohort 2 enrollment is complete. Entrada expects Cohort 1 data after one year of open-label treatment by year-end 2026 and Cohort 2 data in Q1 2027.
Entrada Therapeutics (TRDA) reported that ENTR-601-45 met safety and tolerability objectives in the first cohort of its Phase 1/2 DMD study. Eight participants received three doses of 5 mg/kg or placebo in ELEVATE-45-201. Treated participants had a 0.10% mean increase in dystrophin, a muscle-supporting protein, versus a 0.02% mean decrease with placebo. Exon skipping increased by a mean 0.15% versus a 0.04% mean decrease with placebo.
One participant experienced two serious adverse events, vomiting and fever, which resolved. No participants discontinued, and all entered the open-label phase. No functional benefit was observed after three doses, consistent with company expectations. Cohort 2 enrollment is complete and dosing at 10 mg/kg is ongoing; Entrada expects data in the first half of 2027, followed by Cohort 3 data at up to 15 mg/kg. The company expects higher doses to increase dystrophin production and provide functional benefit.
Entrada Therapeutics (TRDA) named Parent Project Muscular Dystrophy and Duchenne Parent Project Netherlands as the 2026 recipients of its DREAMS Grant Program, which awards two $50,000 grants to non-profit projects addressing disparities in the Duchenne muscular dystrophy community.
PPMD will use its grant to apply findings from a national Care Landscape Assessment across its Certified Duchenne Care Center network, aiming to improve access to coordinated, multidisciplinary care, particularly for adults and people in rural U.S. communities. Funds will support adult care infrastructure, multilingual resources, provider education and community engagement.
Duchenne Parent Project Netherlands will expand its Duchenne Barrier Breaker early-intervention program, embedding personalized coaching into routine Duchenne care in the Netherlands to promote autonomy, self-confidence and social participation during the transition to adulthood. An independent, multi-country Grant Review Committee of clinicians, advocates and individuals living with Duchenne selected the recipients.
Entrada Therapeutics (TRDA) granted equity inducement awards to eight newly hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026.
The awards comprise an aggregate of 61,365 RSUs and options to purchase 19,425 shares of common stock, with an exercise price of $7.07 per share, equal to the closing price on August 31, 2026. The Compensation Committee approved these grants as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Options vest 25% on the first anniversary of the vesting commencement date and 75% in 36 equal monthly installments thereafter, fully vesting on the fourth anniversary, subject to continued employment. RSUs vest 25% after one year and 6.25% quarterly on March 1, June 1, September 1 and December 1, subject to continuous service, all under the plan and award agreements.
Entrada Therapeutics (Nasdaq: TRDA) reported second quarter 2026 results and detailed progress across its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) pipeline. Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, versus $295.7 million at year-end 2025, and the company expects this to fund operations into the third quarter of 2027.
Collaboration revenue was $0.9 million, down from $2.0 million a year earlier. R&D expenses were $35.4 million and G&A expenses $10.5 million, both modestly lower year over year, resulting in a net loss of $42.8 million compared to $43.1 million. Entrada highlighted multiple upcoming data readouts from its ELEVATE-44-201, ELEVATE-45-201 and DM1 collaboration study (VX-670) between late 2026 and early 2027, as well as new regulatory clearances for additional exon-skipping DMD candidates.
Entrada Therapeutics (Nasdaq: TRDA) reported that an independent Data Monitoring Committee reviewed safety and PK data from eight participants in Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for Duchenne muscular dystrophy.
The committee recommended initiating Cohort 2 at an escalated dose of 10 mg/kg, up from 5 mg/kg. Participants from Cohort 1 have progressed to the open-label Phase 2 portion, and Entrada remains on track to share Cohort 1 safety, PK and dystrophin data in mid-2026.
Entrada Therapeutics (Nasdaq: TRDA) granted 18,600 restricted stock units (RSUs) to three newly hired non-executive employees under its 2025 Inducement Equity Plan, effective June 1, 2026.
The RSUs vest 25% after one year, then 6.25% quarterly, subject to continued service.
Entrada (Nasdaq: TRDA) reported Q1 2026 results and highlighted positive topline Cohort 1 data from the Phase 1/2 ELEVATE-44-201 study in Duchenne muscular dystrophy, showing favorable safety, tolerability and early functional benefit at 6 mg/kg.
The company held $254.9 million cash on March 31, 2026, and expects runway into Q3 2027. Entrada plans additional mid‑2026 and year‑end clinical readouts and continues regulatory and clinical preparations for multiple exon‑skipping programs.
Entrada Therapeutics (Nasdaq: TRDA) reported positive topline Phase 1/2 ELEVATE-44-201 Cohort 1 results for ENTR-601-44 in ambulatory DMD patients amenable to exon 44 skipping. Cohort 1 (6 mg/kg) showed favorable safety, no SAEs or discontinuations, a mean 2.36% dystrophin increase from 4.00% baseline, a 2.31% exon skipping increase from 2.66% baseline, and a statistically significant improvement in Time to Rise (TTR) velocity. Pharmacokinetics in juveniles were lower than adults; the company has started Cohort 2 at 12 mg/kg and expects additional data by year-end 2026.
Entrada Therapeutics (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 on May 7, 2026.
The company will host an investor webcast and conference call at 8:30 a.m. ET; the webcast is available via the Investor Relations section of the company website and will be archived for 90 days.